Diadem appoints Michael Rasche as CEO

MILAN, July 10, 2024 (GLOBE NEWSWIRE) — Diadem SpA (Diadem), a company developing one of the first blood tests to early and accurately predict the clinical progression of Alzheimer’s disease (AD), today announced that Michael Rasche has been appointed Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Rasche brings to Diadem more than three decades of experience driving life science innovation to commercial success in Europe and the Americas. The Company also announced that former Chief Executive Officer Paul Kinnon will continue to serve on the Board of Directors of Diadem SpA and has been appointed Chairman of Diadem US, Inc.

Dr. Gerald Möller, Chairman of the Board of Directors of Diadem, commented: “I am delighted that Michael will lead Diadem at this exciting time for the company. Michael’s extensive experience includes leadership roles in market development, sales and general management in our industry. His determination, skills and commitment have enabled him to successfully commercialize numerous innovative products. The growing number of treatment options for AD underscores the importance of early identification and monitoring of patients with Alzheimer’s disease, with increasing evidence that early interventions can slow disease progression. Our AlzoSure® The predictive test can accurately identify individuals who will develop AD years before the disease manifests. With Michael on board and Paul’s continued guidance, we will be optimally prepared for Diadem’s upcoming growth phase.

Mr. Rasche noted, “I am excited to lead Diadem as we rapidly commercialize AlzoSure.® products – a truly innovative approach to improving the management of Alzheimer’s disease. Diadem has already collected an impressive amount of clinical data that demonstrates the accuracy and usefulness of AlzoSure® as a prognostic test for AD, and our research also suggests additional applications. I look forward to working with our team and our partners to grow our business and ensure that the benefits of AlzoSure® are widely available to relevant stakeholders worldwide.”

Michael Rasche has over 30 years of leadership experience in high-growth, international healthcare and life sciences companies in Europe and the Americas. He was most recently Chief Commercial Officer of transformational diagnostics company miDiagnostics. Previously, Rasche was President and Chief International Officer of Metabolon, where he oversaw operations and commercial operations during a period of rapid growth. At Definiens, an AstraZeneca company, Rasche helped grow the business as Chief Commercial Officer, achieving 50% growth and setting the stage for major partnerships. He has also held senior positions at Ayoxxa, Dako (now part of Agilent), Roche and Bayer Diagnostics.

AlzoSure by Diadem® Predict is a noninvasive biomarker blood test that can accurately predict whether people over age 50 will experience significant cognitive decline due to Alzheimer’s disease up to six years before symptoms appear. Its utility is supported by clinical data from a large longitudinal study that formed the basis for AlzoSure® Predict CE-IVD Certification and Breakthrough Device Designation from the U.S. Food and Drug Administration. Diadem enters into strategic partnership, granting Quest Diagnostics exclusive rights to AlzoSure IP in the U.S.® Predicting mass spectrometry results to develop, validate, and commercialize a laboratory-developed testing service for U.S. providers and patients.

About AlzoSure® Technology
AlzoSure® Predict uses a proprietary antibody (U-p53UNTIL) to measure the blood levels of a conformational variant of the p53 protein, which has been linked to the pathogenesis of AD. The utility of AlzoSure® The Predict tool is based on a large amount of clinical data, including: data from the longitudinal study that formed the basis for AlzoSure® Predict’s Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and EU CE-IVD Marking for AlzoSure® Predict requires only 1 ml of blood to detect the risk of Alzheimer’s disease in the asymptomatic and early symptomatic stages. In addition, AlzoSure® Predict products can identify “rapidly progressing” individuals at high risk of developing Alzheimer’s within two years. Diadem is also developing AlzoSure® Confirm to differentiate the diagnosis of Alzheimer’s disease from other dementias. AlzoSure® Confirm is a blood-based test that uses a different set of protein fingerprints to measure levels of unfolded p53 protein to distinguish and predict whether individuals will develop AD, frontotemporal dementia, Lewy body dementia, or Parkinson’s disease dementia. Clinical validation studies are ongoing.

About the Diadem
Diadem was founded as a spin-out from the University of Brescia, Italy. The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer’s disease. The lack of accurate, accessible and affordable diagnostic tools has contributed to the lack of effective treatments for this devastating disease. As a result, patients are not diagnosed until late in the disease, when effective treatment is less feasible. Diadem’s fast, accurate and affordable AlzoSure test® The Predict blood-based prognostic test enables early identification of patients in the disease process, when effective interventions and improved outcomes are potentially possible. The utility of this approach has been demonstrated in long-term clinical studies, which were the basis for CE-IVD marking in the EU and Breakthrough Device designation in the US. Additional retrospective and prospective clinical studies are ongoing to further validate the clinical claims and support adoption and use. The company is also developing AlzoSure® Confirm, a blood-based AD diagnostic test that has shown promising results in early studies. For more information, visit

The photo accompanying this ad is available at


Michael Rasche
General Director
Executive [email protected]
Barbara Lindheim
BLL collaborates with Diadem
[email protected]
+1 (917) 355-9234